Sanofi (SAN) Stock Forecast & Price Target

Compare

215 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SAN Analyst Ratings

Moderate Buy

9 Buy

5 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Sanofi

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SAN Stock 12 Month Forecast

Average Price Target

€112.00

▲(39.41%Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Sanofi in the last 3 months. The average price target is €112.00 with a high forecast of €125.79 and a low forecast of €96.37. The average price target represents a 39.41% change from the last price of €80.34.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"79":"€79","126":"€126","90.75":"€90.8","102.5":"€102.5","114.25":"€114.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125.78541438935628,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€125.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112.0048444149,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€112.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":96.36785779829715,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€96.37</span>\n  </div></div>","useHTML":true}}],"tickPositions":[79,90.75,102.5,114.25,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.34,83.83580110687356,87.33160221374712,90.82740332062068,94.32320442749425,97.8190055343678,101.31480664124136,104.81060774811492,108.30640885498848,111.80220996186205,115.2980110687356,118.79381217560916,122.28961328248272,{"y":125.78541438935628,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.34,82.77575726268462,85.21151452536924,87.64727178805384,90.08302905073846,92.51878631342308,94.9545435761077,97.39030083879231,99.82605810147693,102.26181536416155,104.69757262684615,107.13332988953077,109.56908715221539,{"y":112.0048444149,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.34,81.57291213833055,82.8058242766611,84.03873641499165,85.27164855332221,86.50456069165276,87.7374728299833,88.97038496831385,90.2032971066444,91.43620924497495,92.66912138330551,93.90203352163606,95.1349456599666,{"y":96.36785779829715,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":91.02,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.436,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.535,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.536,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.946,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.785,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.995,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.957,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.716,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.854,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€125.79

Average Price Target€112.00

Lowest Price Target€96.37

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

€89

Buy

10.78%

Upside

Reiterated

08/01/25

Sanofi's strong financial performance, attractive valuation, and positive earnings call guidance drive a favorable overall score. The technical analysis indicates short-term bearish sentiment, but the company's robust fundamentals and growth potential mitigate these concerns. Investors should consider the potential impact of increased operational expenses and external factors such as U.S. tariffs.

Matthew WestonUBS

UBS

€115

Buy

43.14%

Upside

Reiterated

08/01/25

UBS Sticks to Their Buy Rating for Sanofi (SNYNF)

Florent CespedesBernstein

Bernstein

€124

Buy

54.34%

Upside

Reiterated

08/01/25

Sanofi (SNYNF) Gets a Buy from Bernstein

Nicolas PauillacKepler Capital

Kepler Capital

€95

Hold

18.25%

Upside

Reiterated

07/31/25

Analysts Are Neutral on Top Healthcare Stocks: Bausch Health Companies (BHC), Sanofi (SNYNF)

Elmar KrausDZ BANK AG

DZ BANK AG

―

Buy

―

Reiterated

07/31/25

DZ BANK AG Sticks to Their Buy Rating for Sanofi (SNYNF)

Sachin JainBank of America Securities

Bank of America Securities

€115

Buy

43.14%

Upside

Reiterated

07/31/25

Sanofi's Growth Potential and Strategic Moves Justify Buy Rating Amidst Margin Concerns

Faisal KhurshidLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

07/28/25

Sanofi's Amlitelimab: A Promising Blockbuster in Atopic Dermatitis Trials Boosting Buy Rating

Emmanuel PapadakisDeutsche Bank

Deutsche Bank

€100

Hold

24.47%

Upside

Reiterated

07/23/25

Deutsche Bank Sticks to Its Hold Rating for Sanofi (SNYNF)

Richard VosserJ.P. Morgan

J.P. Morgan

€110

Hold

36.92%

Upside

Reiterated

07/17/25

J.P. Morgan Keeps Their Hold Rating on Sanofi (SNYNF)

Luisa HectorBerenberg Bank

Berenberg Bank

€118

Buy

46.88%

Upside

Reiterated

07/03/25

Analysts Offer Insights on Healthcare Companies: AbSci (NASDAQ: ABSI) and Sanofi (Other OTC: SNYNF)

James QuigleyGoldman Sachs

Goldman Sachs

€117→€103

Hold

28.21%

Upside

Reiterated

07/03/25

Sanofi (SNYNF) Receives a Hold from Goldman Sachs

Emily FieldBarclays

Barclays

€125→€115

Buy

43.14%

Upside

Reiterated

07/02/25

Barclays Sticks to Their Buy Rating for Sanofi (SNYNF)

Benjamin Jackson CFAJefferies

Jefferies

€120

Buy

49.37%

Upside

Reiterated

06/05/25

Jefferies Reaffirms Their Buy Rating on Sanofi (SNYNF)

Seamus FernandezGuggenheim

Guggenheim

€108→€110

Buy

36.92%

Upside

Reiterated

06/02/25

Guggenheim Reaffirms Their Buy Rating on Sanofi (SNYNF)

Unknown AnalystMorgan Stanley

Not Ranked

Morgan Stanley

€100

Hold

24.47%

Upside

Initiated

06/02/25

Sanofi (SNYNF) Has a New Rating from Morgan Stanley

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

€89

Buy

10.78%

Upside

Reiterated

08/01/25

Matthew WestonUBS

UBS

€115

Buy

43.14%

Upside

Reiterated

08/01/25

UBS Sticks to Their Buy Rating for Sanofi (SNYNF)

Florent CespedesBernstein

Bernstein

€124

Buy

54.34%

Upside

Reiterated

08/01/25

Sanofi (SNYNF) Gets a Buy from Bernstein

Nicolas PauillacKepler Capital

Kepler Capital

€95

Hold

18.25%

Upside

Reiterated

07/31/25

Analysts Are Neutral on Top Healthcare Stocks: Bausch Health Companies (BHC), Sanofi (SNYNF)

Elmar KrausDZ BANK AG

DZ BANK AG

―

Buy

―

Reiterated

07/31/25

DZ BANK AG Sticks to Their Buy Rating for Sanofi (SNYNF)

Sachin JainBank of America Securities

Bank of America Securities

€115

Buy

43.14%

Upside

Reiterated

07/31/25

Sanofi's Growth Potential and Strategic Moves Justify Buy Rating Amidst Margin Concerns

Faisal KhurshidLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

07/28/25

Sanofi's Amlitelimab: A Promising Blockbuster in Atopic Dermatitis Trials Boosting Buy Rating

Emmanuel PapadakisDeutsche Bank

Deutsche Bank

€100

Hold

24.47%

Upside

Reiterated

07/23/25

Deutsche Bank Sticks to Its Hold Rating for Sanofi (SNYNF)

Richard VosserJ.P. Morgan

J.P. Morgan

€110

Hold

36.92%

Upside

Reiterated

07/17/25

J.P. Morgan Keeps Their Hold Rating on Sanofi (SNYNF)

Luisa HectorBerenberg Bank

Berenberg Bank

€118

Buy

46.88%

Upside

Reiterated

07/03/25

Analysts Offer Insights on Healthcare Companies: AbSci (NASDAQ: ABSI) and Sanofi (Other OTC: SNYNF)

James QuigleyGoldman Sachs

Goldman Sachs

€117→€103

Hold

28.21%

Upside

Reiterated

07/03/25

Sanofi (SNYNF) Receives a Hold from Goldman Sachs

Emily FieldBarclays

Barclays

€125→€115

Buy

43.14%

Upside

Reiterated

07/02/25

Barclays Sticks to Their Buy Rating for Sanofi (SNYNF)

Benjamin Jackson CFAJefferies

Jefferies

€120

Buy

49.37%

Upside

Reiterated

06/05/25

Jefferies Reaffirms Their Buy Rating on Sanofi (SNYNF)

Seamus FernandezGuggenheim

Guggenheim

€108→€110

Buy

36.92%

Upside

Reiterated

06/02/25

Guggenheim Reaffirms Their Buy Rating on Sanofi (SNYNF)

Unknown AnalystMorgan Stanley

Not Ranked

Morgan Stanley

€100

Hold

24.47%

Upside

Initiated

06/02/25

Sanofi (SNYNF) Has a New Rating from Morgan Stanley

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sanofi

1 Month

xxx

Success Rate

5/9 ratings generated profit

Average Return

+0.66%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +0.66% per trade.

3 Months

xxx

Success Rate

7/10 ratings generated profit

Average Return

+1.04%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +1.04% per trade.

1 Year

Seamus FernandezGuggenheim

Success Rate

8/9 ratings generated profit

Average Return

+9.70%

reiterated a buy rating 2 months ago

Copying Seamus Fernandez's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +9.70% per trade.

2 Years

xxx

Success Rate

13/23 ratings generated profit

Average Return

+6.07%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 56.52% of your transactions generating a profit, with an average return of +6.07% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SAN Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SAN has received 24 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. SAN average Analyst price target in the past 3 months is 112.00.

Each month's total comprises the sum of three months' worth of ratings.

SAN Financial Forecast

SAN Earnings Forecast

Next quarter’s earnings estimate for SAN is €2.89 with a range of €2.72 to €3.07. The previous quarter’s EPS was €1.59. SAN beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 48.72% of the time in the same period. In the last calendar year SAN has Outperformed its overall industry.

SAN Sales Forecast

Next quarter’s sales forecast for SAN is €13.06B with a range of €12.38B to €13.59B. The previous quarter’s sales results were €19.89B. SAN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 54.24% of the time in the same period. In the last calendar year SAN has Outperformed its overall industry.

SAN Stock Forecast FAQ

What is FR:SAN’s average 12-month price target, according to analysts?

Based on analyst ratings, Sanofi’s 12-month average price target is 112.00.

What is FR:SAN’s upside potential, based on the analysts’ average price target?

Sanofi has 39.41% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Sanofi a Buy, Sell or Hold?

Sanofi has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 5 hold ratings and 0 sell ratings.

What is Sanofi’s share price target?

The average share price target for Sanofi is 112.00. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €125.79 ,and the lowest forecast is €96.37. The average share price target represents 39.41% Increase from the current price of €80.34.

What do analysts say about Sanofi?

Sanofi’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of Sanofi?

To buy shares of FR:SAN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Sanofi (SAN) Stock Forecast & Price Target

SAN Analyst Ratings

SAN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sanofi

SAN Analyst Recommendation Trends

SAN Financial Forecast

SAN Earnings Forecast

SAN Sales Forecast

SAN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts